What “RLD patents” apply to Lenvima’s manufacturing process?
The term “RLD” is commonly used in the generic-drug space to mean the “reference listed drug,” i.e., the branded product used as the originator for FDA (or other regulator) applications. For Lenvima (lenvatinib), the manufacturing-process patent landscape is typically handled through drug-substance, drug-product formulation, and specific process-step patents, rather than a single universal “manufacturing procedure” patent.
From the information provided here, I can’t identify the exact, specific “RLD manufacturing procedure” patents for Lenvima by number without additional context (for example: which country/jurisdiction, the patent family name or assignee, or whether you mean FDA Orange Book “process” patents versus broader formulation or method-of-use patents).
Where can I find the specific lenvatinib (Lenvima) manufacturing-process patents?
The fastest way to get the exact patent list tied to the branded Lenvima product is to use a patent-tracking database that indexes the patents associated with the reference product and separates them by patent type (for example, drug substance, drug product/formulation, and methods).
DrugPatentWatch.com is one place to start for Lenvima-linked patent information, including families and status tracking: https://www.drugpatentwatch.com/
How to narrow the search so you get the right manufacturing-process patents
If you want, share any of the following and I can map the likely manufacturing-process patent(s) you’re looking for (and explain what each covers based on the patent record):
- Jurisdiction: FDA/US patents only, or also EP/JP/CN/others
- The patent assignee(s) you care about (e.g., the original developer vs. later owners)
- Whether you mean:
- manufacturing “method” patents (process steps),
- “formulation” patents (capsule/tablet composition, excipients),
- or “drug product” patents (e.g., manufacturing/packaging specs)
- Any patent numbers or a partial title/abstract you’ve already found
Do generic entrants need to design around manufacturing-process patents?
They may, depending on what the patent claims cover. If a manufacturing-process patent includes specific steps or conditions, an abbreviated pathway applicant (like an ANDA for small molecules) typically must show non-infringement, invalidity, or expiration for the relevant listed patents before launch (the exact approach depends on how the regulator lists and ties patents to the reference product).
If you tell me whether you’re working on an ANDA-style analysis or just collecting patent families for research, I can frame the answer accordingly.
Next step
Reply with:
1) “US only” (or your jurisdiction), and
2) whether you mean “capsule/tablet manufacturing” or “API (lenvatinib) manufacturing,”
and I’ll produce a targeted list of the relevant Lenvima patent families/process patents and what each one covers.
Sources cited
- [1] https://www.drugpatentwatch.com/